Plus   Neg

Stock Alert: Translate Bio

Shares of a clinical-stage messenger RNA (mRNA) therapeutics company, Translate Bio, Inc. (TBIO) gapped up nearly 12% at $11.48 Friday morning after the company announced that French pharmaceutical giant Sanofi is collaborating with Translate Bio to develop a novel mRNA vaccine for COVID-19.

TBIO is currently trading at $10.70, up 4.39%. It has traded in the range of$6.80- $14.34 in the past 52-weeks.

Translate Bio has begun to produce multiple mRNA constructs and will use its mRNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates.

The shares of Translate Bio have been increasing from February end after the FDA has granted Fast Track designation for its drug candidate, MRT5005 for the treatment of cystic fibrosis (CF). It has gained nearly 45% since then.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT